NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Aura Biosciences, Inc. (AURA) Stock Analysis

Aura Biosciences, Inc. (AURA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AURA

$6.46

−$0.10 (−1.52%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AURA with… →

AURA Key Statistics

As of Oct 21, 2026
Trading
Open
$6.56
Previous Close
$6.56
Day's Range
6.39–6.61
52-Week Range
4.73–9.54
Volume
933.55K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.41
Valuation
Market Cap
$669.93M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.75
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$106.19M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.70M
1-Year Return
+5.56%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
816.91K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AURA closed at $6.46, +5.56% over 1 year.

Aura Biosciences, Inc. (AURA) has a market capitalization of $669.93M.

In fiscal 2025, AURA reported revenue of $0.00.

AURA Stock Return by Calendar Year

Aura Biosciences, Inc. (AURA) return since Oct 2021: what $10,000 became

1 year
$10,000 $10,556
+5.56%
5 years
$10,000 $4,365
−56.35%

If you had invested $10,000 in Aura Biosciences, Inc. (AURA) at the close on October 29, 2021, the earliest close on record here, it would have been worth $4,365 at the close on October 21, 2026: −56.35% in total, −15.28% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.53%
2025−33.70%
2024−7.22%
2023−15.62%
2022−38.16%
2021 (partial year)+14.73%

As of October 21, 2026.

AURA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$106.19M—
2024$0.00−$86.92M—
2023$0.00−$76.41M—
2022$0.00−$58.76M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$112.79M−$106.19M—
2024$0.00—−$96.12M−$86.92M—
2023$0.00—−$84.99M−$76.41M—
2022$0.00—−$60.30M−$58.76M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aura Biosciences, Inc. (AURA) is capitalised at $669.93M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 113 employees.

The 52-week range on file runs from $4.73 to $9.54. AURA last closed at $6.46 on October 21, 2026. That is −$0.10 (−1.52%) against the previous close. The latest close sits 36.58% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $106.19M. Earnings per share on a trailing basis come to −1.75.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.41. Annualized volatility over the trailing 5 years is 68.43%. Over the trailing twelve months the total return is +5.56%. Across 5 years the annualized return works out at −15.28%.

Growth & Income

No dividend is on file for AURA.

So far in 2026 the total return is +18.53%. The strongest complete calendar year on file is 2024 at −7.22%; the weakest is 2022 at −38.16%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Aura Biosciences, Inc. (AURA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aura Biosciences, Inc. AURA $669.93M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Aura Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aura Biosciences, Inc.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Visit website →